The new network will reach nearly 40 million patients in the US. Credit: CDC on Unsplash.

Veradigm and PRA Health Sciences have partnered to establish an electronic healthcare record (EHR)-based clinical research network in the US.

The new network will reach around 25,000 physicians and 40 million patients across the country.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It leverages Veradigm’s StudySource platform, which boosts current EHR systems to comprise clinical research, along with PRA’s eSource technology and clinical research capabilities.

Physicians can use the network to provide clinical research as a care option (CRACCO) to their patients. This approach could improve clinical trials’ process efficacies, accessibility and diversity.

Veradigm Life Sciences Research business vice-president and general manager Stephanie Reisinger said: “Under this agreement, the Veradigm and PRA-led network aims to transform the clinical research processes by extending EHR workflows to include clinical research as well as fully leveraging the rich data from digital healthcare delivery.

“The scale of Veradigm’s EHR footprint with PRA’s eSource technology and deep trial expertise will enable us to literally bring studies to where the patients are.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Data management and tracking are considered long and expensive steps of a trial but most of this information is already available in EHR systems, Veradigm noted.

PRA Health’s eSource technology can automatically transfer data from Veradigm’s EHRs to an electronic data capture system, in turn expediting drug development via reduced time and effort in this step.

The automated process could also decrease transcription errors and enhance data quality while mitigating the expensive verification of source data.

PRA Health Sciences executive vice-president and chief scientific officer Kent Thoelke said: “We are evolving and modernising the drug development paradigm by integrating it with everyday healthcare delivery.”

In February this year, Irish company ICON entered an agreement to acquire PRA Health Sciences in a cash and stock deal valued at about $12bn.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact